Hamps Bio Ltd

Hamps Bio Ltd has submitted its Annual Report for the financial year 2025-26, as per SEBI regulations. The report, which includes the Notice of the 19th Annual General Meeting, has been sent to members electronically and is also available on the company's website. The filing details corporate information, board of directors, financial performance highlights, auditor reports, and product overview. The company's registered office is in Ankleshwar, Gujarat, with a corporate office in Surat.

Hamps Bio Limited has announced its 19th Annual General Meeting (AGM) to be held on September 9, 2026, at 12:00 PM at its registered office in Ankleshwar, Gujarat. The meeting agenda includes the adoption of audited standalone and consolidated financial statements for the fiscal year 2025-26, the re-appointment of Mrs. Pallavi Herrik Shah as a director, and a special business item to approve the shifting of the company's registered office from Bharuch, Ankleshwar to Surat, Gujarat. The notice also details proxy appointment rules for attending members.

Hamps Bio Ltd's Board of Directors met on August 12, 2026, approving the Board of Directors Report and the draft Annual Report for the financial year ended March 31, 2026. The board also approved the notice for the 19th Annual General Meeting (AGM) scheduled for September 9, 2026. Key decisions included recommending the re-appointment of Director Mrs. Pallavi Herrik Shah, proposing a shift of the registered office from Ankleshwar to Surat, and appointing M/s. Richa Goyal & Associates as Scrutinizer for the AGM. A cut-off date was also fixed for determining member eligibility for voting and attendance at the AGM.

Hamps Bio Ltd has filed an intimation under Regulation 30(5) of SEBI LODR to update the contact details of its Key Managerial Personnel (KMP). These individuals are authorized to determine the materiality of events and make disclosures to the stock exchanges. The updated contact information includes Mr. Herrik Mountbaton Shah (Managing Director), Mr. Shrenikkumar Mountkumar Shah (Whole-time Director), Mrs. Mitali Shrenikkumar Shah (Chief Financial Officer), and Mr. Ravi Baheti (Company Secretary & Compliance Officer). The company has also made this information available on its website, www.hampsbio.com.

Hamps Bio Ltd announced changes in its key management personnel following a Board Meeting held on July 6, 2026. Ms. Komal Jain resigned as Company Secretary & Compliance Officer, effective June 30, 2026, due to personal reasons. The Board approved the appointment of Mr. Ravi Baheti as her replacement, effective July 6, 2026. Mr. Baheti is an Associate Member of ICSI with over nine years of experience. The Board also authorized Key Managerial Personnel (KMPs) to determine the materiality of events for stock exchange disclosures.

Hamps Bio Limited has re-appointed M/s Naviwala & Associates, Surat, as its Internal Auditor for the Financial Year 2026-27, effective from May 29, 2026. This decision was made during the Board of Directors meeting held on May 29, 2026, and complies with Regulation 30 of the Listing Regulations. Naviwala and Associates, founded in July 2020, has expertise in India's financial landscape.

Hamps Bio Ltd's Board of Directors approved the standalone and consolidated audited financial results for the half year and financial year ended March 31, 2026. The board also took note of the auditor’s report with an unmodified opinion issued by M/s MGHVS & ASSOCIATES. Additionally, M/s Naviwala & Associates, Surat, were appointed as the Internal Auditor for the Financial Year 2026-2027.

Hamps Bio Ltd has scheduled a Board of Directors meeting on May 29, 2026, to consider and approve the audited standalone and consolidated financial results for the half year and year ended March 31, 2026. The board will also consider the appointment of Naviwala & Associates as internal auditor for the financial year 2026-2027.

Hamps Bio Ltd has announced the closure of the trading window for all Designated Persons, Directors and their immediate relatives. The closure is in accordance with the SEBI (Prohibition of Insider Trading) Regulations, 2015, and the Company's code of conduct. The trading window will remain closed from Wednesday, April 01, 2026 till 48 hours after the announcement/declaration of Audited Standalone and Consolidated Financial Results for half year and year ended on 31st March, 2026. The date of the Board Meeting at which the said results will be considered is yet to be intimated.

Hamps Bio Ltd has announced the completion of the acquisition of 100% equity shares of HSDL Innovative Private Limited. The total purchase consideration for this acquisition is INR 2,04,00,000. This acquisition has resulted in HSDL Innovative Private Limited becoming a Wholly Owned Subsidiary of Hamps Bio Ltd. The acquisition was completed on 25th March 2026. The necessary information has been provided to the Stock Exchange(s) as per Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI Master Circular no. HO/49/14/14(7)2025-CFD- POD2/I/3762/2026 dated January 30, 2026.